KR102936358B1 - 소아용 트라조돈 조성물 및 이의 치료 방법 - Google Patents

소아용 트라조돈 조성물 및 이의 치료 방법

Info

Publication number
KR102936358B1
KR102936358B1 KR1020227011618A KR20227011618A KR102936358B1 KR 102936358 B1 KR102936358 B1 KR 102936358B1 KR 1020227011618 A KR1020227011618 A KR 1020227011618A KR 20227011618 A KR20227011618 A KR 20227011618A KR 102936358 B1 KR102936358 B1 KR 102936358B1
Authority
KR
South Korea
Prior art keywords
trazodone
pharmaceutical composition
pediatric
paragraph
children
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227011618A
Other languages
English (en)
Korean (ko)
Other versions
KR20220080096A (ko
Inventor
파브리치오 칼리스티
로렐라 라니
세레나 톤지아니
로셀라 피콜로
라우라 오기아누
Original Assignee
안젤리니 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안젤리니 에스.피.에이. filed Critical 안젤리니 에스.피.에이.
Publication of KR20220080096A publication Critical patent/KR20220080096A/ko
Application granted granted Critical
Publication of KR102936358B1 publication Critical patent/KR102936358B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227011618A 2019-09-26 2020-09-25 소아용 트라조돈 조성물 및 이의 치료 방법 Active KR102936358B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906166P 2019-09-26 2019-09-26
US62/906,166 2019-09-26
PCT/EP2020/077017 WO2021058810A1 (en) 2019-09-26 2020-09-25 Pediatric trazodone compositions and method of treatment thereof

Publications (2)

Publication Number Publication Date
KR20220080096A KR20220080096A (ko) 2022-06-14
KR102936358B1 true KR102936358B1 (ko) 2026-03-10

Family

ID=72665264

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011618A Active KR102936358B1 (ko) 2019-09-26 2020-09-25 소아용 트라조돈 조성물 및 이의 치료 방법

Country Status (13)

Country Link
US (1) US12514856B2 (enExample)
EP (1) EP4034117A1 (enExample)
JP (1) JP7629453B2 (enExample)
KR (1) KR102936358B1 (enExample)
CN (1) CN114615983A (enExample)
AU (1) AU2020354534B2 (enExample)
BR (1) BR112022005343A2 (enExample)
CA (1) CA3153639A1 (enExample)
GE (2) GEP20257739B (enExample)
IL (1) IL291548A (enExample)
MX (1) MX2022003442A (enExample)
UA (1) UA129270C2 (enExample)
WO (1) WO2021058810A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240173315A1 (en) * 2022-11-14 2024-05-30 OWP Pharmaceuticals, Inc. Trazodone oral solution
US20240390277A1 (en) * 2023-04-15 2024-11-28 Rubicon Research Private Limited Liquid formulations of trazodone
CN119280155B (zh) * 2024-12-11 2025-02-25 新基元(北京)医药科技有限公司 一种改善稳定性的盐酸曲唑酮液体药物组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016069A2 (en) * 2007-07-31 2009-02-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Stable liquid pharmaceutical composition based on trazodone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1931346T1 (sl) 2005-09-09 2012-10-30 Angelini Labopharm Llc Trazodonski sestavek za dajanje enkrat dnevno
ITMI20071603A1 (it) 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016069A2 (en) * 2007-07-31 2009-02-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Stable liquid pharmaceutical composition based on trazodone

Also Published As

Publication number Publication date
JP2022549473A (ja) 2022-11-25
IL291548A (en) 2022-05-01
JP7629453B2 (ja) 2025-02-13
CA3153639A1 (en) 2021-04-01
GEAP202415936A (en) 2024-10-28
WO2021058810A1 (en) 2021-04-01
MX2022003442A (es) 2022-07-11
BR112022005343A2 (pt) 2022-06-14
GEP20257739B (en) 2025-02-25
US12514856B2 (en) 2026-01-06
EP4034117A1 (en) 2022-08-03
KR20220080096A (ko) 2022-06-14
US20220331312A1 (en) 2022-10-20
UA129270C2 (uk) 2025-03-05
AU2020354534B2 (en) 2025-10-02
CN114615983A (zh) 2022-06-10
AU2020354534A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
Fabiano et al. Paediatric pharmacology: remember the excipients
ES2929133T3 (es) Composiciones y métodos para la absorción transmucosa
Cuzzolin Neonates exposed to excipients: concern about safety
Ursino et al. Excipients in medicinal products used in gastroenterology as a possible cause of side effects
Dash et al. Use of sorbitol as pharmaceutical excipient in the present day formulations–issues and challenges for drug absorption and bioavailability
US12514856B2 (en) Pediatric trazodone compositions and method of treatment thereof
Nielsen et al. Topical morphine for oral mucositis in children: dose finding and absorption
Marçon et al. Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin
EA029478B1 (ru) Стабильные растворы объединенных активных фармацевтических ингредиентов для перорального применения
Van der Vossen et al. Design and stability study of an oral solution of amlodipine besylate for pediatric patients
Van Hecken et al. Relative bioavailability of enalapril administered as orodispersible minitablets in healthy adults
RU2625550C2 (ru) Ароматизированное анисом лекарственное средство
De Goede et al. Development and validation of a paediatric oral formulation of clonidine hydrochloride
JP6410814B2 (ja) フェキソフェナジンを含む経口投与用液体医薬組成物
Dao et al. Novel Patient‐Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use
Li et al. Pediatric cardiovascular drug trials, lessons learned
EA047917B1 (ru) Композиции тразодона для применения в педиатрии и способ лечения ими
Anderson Neonatal pharmacology
Sawant et al. A randomized pilot study to evaluate the stability, taste, and palatability of a novel liquid formulation of tenapanor
Weisler et al. Fed and Fasted Administration of a Novel Extended‐Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD
CN115645357A (zh) 一种拉考沙胺口服溶液处方及其制备工艺
RU2854144C1 (ru) Фармацевтическая композиция твердой дозированной лекарственной формы, содержащая пропранолола гидрохлорид
JP7627353B2 (ja) チザニジン液体製剤及びその用途
US12042484B2 (en) Tizanidine liquid preparation and use thereof
Bersagui et al. Development and Stability Assessment of Alternative Sugar-Free Pediatric Solution Containing Losartan Potassium

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)